Biohaven Ltd. (NYSE: BHVN) has taken center stage in the biopharmaceutical sector after releasing positive results from its ...

(Reuters) - Biohaven has met the main goal in a study evaluating its drug in patients with an inherited disease that mainly ...

The progressive neurological disease known as spinocerebellar ataxia 4 (SCA4) is a rare condition ... and previous research had located the gene responsible for a specific region of one chromosome.

First clinical data of VO659 demonstrated 28% mean reduction in CSF mutant HTT at day 85 in HD patients in 40 mg dose cohort with an effect after the first dose No sustained ...

Researchers have discovered that the protein mutated in Huntington’s Disease fails to properly repair DNA, leading to reduced brain cell healing.

Atamyo Therapeutics, a biotechnology company focused on the development of new-generation gene therapies targeting neuromuscular disease, today announced its participation in six upcoming conferences ...